Vanguard Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$93.9M Sell
11,266,982
-97,254
-0.9% -$916K ﹤0.01% 1556
2026
Q2
$114M Buy
11,364,236
+228,474
+2% +$2.07M ﹤0.01% 1498
2026
Q1
$106M Buy
+11,135,762
New +$86.5M ﹤0.01% 1441

Other funds holding BCRX

Vanguard Capital Management's BCRX Position: Q3 2026 in Review

Vanguard Capital Management reduced its BioCryst Pharmaceuticals (BCRX) stake by 0.86% in Q3 2026, selling an estimated $916K and leaving 11,266,982 shares worth $93.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1556.

Vanguard Capital Management first reported a position in BCRX in Q1 2026 and has held it in 3 quarters since. The position peaked at $114M in Q2 2026. 334 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

  • Vanguard Capital Management held 11,266,982 shares of BioCryst Pharmaceuticals worth $93.9M as of Q3 2026.
  • Vanguard Capital Management sold 97,254 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $916K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1556 holding.
  • Vanguard Capital Management first reported a position in BioCryst Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's BioCryst Pharmaceuticals position peaked at $114M in Q2 2026.
  • 334 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.